Gene therapy developments for pancreatic cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 2, 2006, Pages 285-298

  Bhattacharyya, Madhumita ^a   Lemoine, Nick R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti angiogenesis; Antisense; Apoptosis; Gene therapy; Oncolytic adenoviruses; Pancreatic cancer; Replication competent; siRNA; Tumour suppressor genes

Indexed keywords

ALPHA INTERFERON; BETA GALACTOSIDASE; CISPLATIN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; INTERLEUKIN 2; ISIS 2503; K RAS PROTEIN; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; NAKED DNA; ONYX 015; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRODRUG; PROTEIN KINASE B; PROTEIN P14ARF; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P53; SMAD4 PROTEIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE; VASCULOTROPIN RECEPTOR 1;

ADENOVIRUS VECTOR; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; CANCER INHIBITION; CLINICAL STUDY; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HUMAN; LIVER TOXICITY; NONHUMAN; ONCOGENE; ONCOLYTIC VIRUS; PANCREAS CANCER; POINT MUTATION; RETROVIRUS VECTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENETIC VECTORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS;

EID: 33645020109     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.10.004     Document Type: Article

References (55)

1. A. Jemal T. Murray T. Ward et. al. Cancer statistics, 2005 CA Cancer J Clin 55 1 2005 10-30
2. M.J. MacKenzie Molecular therapy in pancreatic adenocarcinoma Lancet Oncol 5 9 2004 541-549
3. H.A. Burris III M.J. Moore J. Andersen et. al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 6 1997 2403-2413
4. C. Caldas S.A. Hahn L.T. da Costa et. al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1 1994 27-32
5. M. Schutte R.H. Hruban J. Geradts et. al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 15 1997 3126-3130
6. R.H. Hruban A.D. van Mansfeld G.J. Offerhaus et. al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization Am J Pathol 143 2 1993 545-554
7. T.A. Sohn C.J. Yeo The molecular genetics of pancreatic ductal carcinoma: A review Surg Oncol 9 3 2000 95-101
8. J.R. Kelley M.M. Fraser J.M. Hubbard et. al. CaSm antisense gene therapy: A novel approach for the treatment of pancreatic cancer Anticancer Res 23 3A 2003 2007-2013
9. K. Aoki T. Yoshida T. Sugimura et. al. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity Cancer Res 55 17 1995 3810-3816
10. F. Recchia G. Sica D. Casucci et. al. Advanced carcinoma of the pancreas: Phase II study of combined chemotherapy, beta-interferon, and retinoids Am J Clin Oncol 21 3 1998 275-278
11. J.S. Macdonald J.L. Jacobson M. Modiano et. al. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) +G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group study (SWOG 9413) Invest New Drugs 18 3 2000 269-273
12. K. Hatanaka K. Suzuki Y. Miura et. al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer J Gene Med 6 10 2004 1139-1148
13. R.P. Perez J.W. Smith S.R. Alberts et. al. A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, in patients with advanced pancreatic carcinoma Proc Am Soc Clin Oncol 2001 [Abstr 628]
14. P.A. Burch S.R. Alberts M.T. Schroeder et. al. Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma; a North Central Cancer Treatment Group (NCCTG) phase II trial Proc Am Soc Clin Oncol 2003 [Abstr 1038]
15. J.Q. Cheng B. Ruggeri W.M. Klein et. al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci USA 93 8 1996 3636-3641
16. V. Stoll V. Calleja G. Vassaux et. al. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer Gut 54 1 2005 109-116
17. T. Shichinohe N. Senmaru K. Furuuchi et. al. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y J Surg Res 66 2 1996 125-130
18. M. Takeuchi T. Shichinohe N. Senmaru et. al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice Gene Ther 7 6 2000 518-526
19. M. Bouvet R.J. Bold J. Lee et. al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer Ann Surg Oncol 5 8 1998 681-688
20. R.F. Hwang E.M. Gordon W.F. Anderson D. Parekh Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene Surgery 124 2 1998 143-150
21. M. Cascallo J. Calbo J.L. Gelpi et. al. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer Cancer Gene Ther 7 4 2000 545-556
22. C. Craig M. Kim E. Ohri et. al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells Oncogene 16 2 1998 265-272
23. C.M. Barton A.B. McKie A. Hogg et. al. Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma Mol Carcinog 13 2 1995 61-69
24. S. Kobayashi H. Shirasawa H. Sashiyama et. al. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation Clin Cancer Res 5 12 1999 4182-4185
25. S.A. Hahn A.T. Hoque C.A. Hoskaluk et. al. Homozygous deletion map at 18q21.1 in pancreatic cancer Cancer Res 56 3 1996 490-494
26. T. Yatsuoka M. Sunamura T. Furukawa et. al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma Am J Gastroenterol 95 8 2000 2080-2085
27. D.G. Duda M. Sunamura L.P. Lefter et. al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells Oncogene 22 44 2003 6857-6864
28. U.S. Joshi S.T. Dergham Y.Q. Chen et. al. Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus Pancreas 16 2 1998 107-113
29. D. Evoy E.A. Hirschowitz H.A. Naama et. al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer J Surg Res 69 1 1997 226-231
30. K. Makinen S. Loimas J. Wahlfors et. al. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer J Gene Med 2 5 2000 361-367
31. A. Block S.H. Chen K. Kosai et. al. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors Pancreas 15 1 1997 25-34
32. K. Aoki T. Yoshida N. Matsumoto et. al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene Hum Gene Ther 8 9 1997 1105-1113
33. E. Greco P. Fogar D. Basso et. al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: An incomplete antitumor effect Pancreas 25 2 2002 e21-e29
34. C. Heise D.H. Kirn L. Johnson Replication-selective adenoviruses as oncolytic agents J Clin Invest 105 7 2000 847-851
35. D. Kirn Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer Oncogene 19 56 2000 6660-6669
36. J.R. Bischoff D.H. Kirn A. Williams et. al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 5286 1996 373-376
37. S. Mulvihill R. Warren A. Venook et. al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial Gene Ther 8 4 2001 308-315
38. J.R. Hecht R. Bedford J.L. Abbruzzesse et. al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin Cancer Res 9 2 2003 555-561
39. B.R. Dix S.J. Edwards A.W. Braithwaite et. al. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 75 12 2001 5443-5447
40. C.C. O'Shea L. Johnson B. Bagus et. al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity Cancer Cell 6 6 2004 611-623
41. F. Motoi M. Sunamura L. Ding et. al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus Hum Gene Ther 11 2 2000 223-235
42. M. Oonuma M. Sunamura F. Motoi et. al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors Int J Cancer 102 1 2002 51-59
43. Saito Y, Sunamura M, Motoi F, et al. Oncolytic replication-competent adenovirus suppresses tumour angiogenesis through preserved E1A region. Cancer Gene Ther 2005; 23 Sept.
44. G. Mazzolini C. Qian X. Xie et. al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12 Cancer Gene Ther 6 6 1999 514-522
45. M. Barajas G. Mazzolini G. Genove et. al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 Hepatology 33 1 2001 52-61
46. M. Caruso K. Pham-Nguyen Y.L. Kwong et. al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 93 21 1996 11302-11306
47. B. Sangro G. Mazzolini J. Ruiz et. al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors J Clin Oncol 22 8 2004 1389-1397
48. T. Hoshida M. Sunamura D.G. Duda et. al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor Pancreas 25 2 2002 111-121
49. M. Saimura E. Nagai K. Mizumoto et. al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4 Clin Cancer Res 8 10 2002 3243-3249
50. M. Saimura E. Nagai K. Mizumoto et. al. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice Cancer Gene Ther 9 10 2002 799-806
51. M.H. Katz D.E. Spivack S. Takimoto et. al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter Ann Surg Oncol 10 7 2003 762-772
52. D. Jacob J.J. Davis L. Zhang et. al. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter Cancer Gene Ther 12 2 2005 109-115
53. D. Campani I. Esposito U. Boggi et. al. Bcl-2 expression in pancreas development and pancreatic cancer progression J Pathol 194 2001 444-450
54. Y. Miyamoto R. Hosataani M. Wada et. al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers Oncology 56 1999 73-82
55. M. Ocker D. Neureiter M. Leuders et. al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer Gut 54 2005 1298-1308